{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Méningite carcinomateuse : Questions médicales les plus fréquentes",
"headline": "Méningite carcinomateuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Méningite carcinomateuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-18",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Méningite carcinomateuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs des méninges",
"url": "https://questionsmedicales.fr/mesh/D008577",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs des méninges",
"code": {
"@type": "MedicalCode",
"code": "D008577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.551.240.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Méningite carcinomateuse",
"alternateName": "Meningeal Carcinomatosis",
"code": {
"@type": "MedicalCode",
"code": "D055756",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lidong Jiao",
"url": "https://questionsmedicales.fr/author/Lidong%20Jiao",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Yue Zhao",
"url": "https://questionsmedicales.fr/author/Yue%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China."
}
},
{
"@type": "Person",
"name": "Hui Bu",
"url": "https://questionsmedicales.fr/author/Hui%20Bu",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China."
}
},
{
"@type": "Person",
"name": "Koki Nakashima",
"url": "https://questionsmedicales.fr/author/Koki%20Nakashima",
"affiliation": {
"@type": "Organization",
"name": "Depertment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, 2-4-1, Tsukimi, Fukui-shi, Fukui-ken, Japan."
}
},
{
"@type": "Person",
"name": "Yoshiki Demura",
"url": "https://questionsmedicales.fr/author/Yoshiki%20Demura",
"affiliation": {
"@type": "Organization",
"name": "Depertment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, 2-4-1, Tsukimi, Fukui-shi, Fukui-ken, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Leptomeningeal neuraxis relapse in glioblastoma is an uncommon but not rare event associated with poor outcome.",
"datePublished": "2023-09-15",
"url": "https://questionsmedicales.fr/article/37715122",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-023-03378-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37366925",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol30060442"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.",
"datePublished": "2023-03-04",
"url": "https://questionsmedicales.fr/article/36870951",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-023-10676-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.",
"datePublished": "2022-12-26",
"url": "https://questionsmedicales.fr/article/36610238",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clineuro.2022.107572"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.",
"datePublished": "2023-10-28",
"url": "https://questionsmedicales.fr/article/37897649",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11060-023-04471-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009423"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D016543"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs des méninges",
"item": "https://questionsmedicales.fr/mesh/D008577"
},
{
"@type": "ListItem",
"position": 6,
"name": "Méningite carcinomateuse",
"item": "https://questionsmedicales.fr/mesh/D055756"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Méningite carcinomateuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Méningite carcinomateuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Méningite carcinomateuse",
"description": "Comment diagnostiquer la méningite carcinomateuse ?\nQuels examens d'imagerie sont utilisés ?\nQuels marqueurs tumoraux sont recherchés ?\nQuels symptômes indiquent une méningite carcinomateuse ?\nQuelle est l'importance de l'historique médical ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Méningite carcinomateuse",
"description": "Quels sont les symptômes courants ?\nY a-t-il des signes neurologiques spécifiques ?\nComment se manifeste la douleur ?\nLes symptômes varient-ils selon le type de cancer ?\nPeut-on avoir de la fièvre ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Méningite carcinomateuse",
"description": "Peut-on prévenir la méningite carcinomateuse ?\nComment réduire le risque de cancer ?\nLes vaccinations aident-elles ?\nQuel rôle joue le dépistage ?\nLes facteurs environnementaux influencent-ils ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Méningite carcinomateuse",
"description": "Quel est le traitement principal ?\nDes corticostéroïdes sont-ils utilisés ?\nComment gérer la douleur ?\nY a-t-il des traitements expérimentaux ?\nQuel suivi est nécessaire après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Méningite carcinomateuse",
"description": "Quelles sont les complications possibles ?\nLa méningite carcinomateuse peut-elle être fatale ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il un risque de récidive ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Méningite carcinomateuse",
"description": "Quels cancers sont associés à la méningite carcinomateuse ?\nL'âge influence-t-il le risque ?\nLe sexe joue-t-il un rôle ?\nLes antécédents familiaux sont-ils un facteur ?\nLes traitements antérieurs augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D055756?page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la méningite carcinomateuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par une ponction lombaire et l'analyse du liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner peuvent aider à visualiser les anomalies cérébrales associées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont recherchés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme le CA 15-3 ou le CA 19-9 peuvent être évalués dans le LCR."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une méningite carcinomateuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maux de tête, des nausées, et des troubles neurologiques peuvent alerter."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'historique médical ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un antécédent de cancer est crucial pour orienter le diagnostic vers une méningite carcinomateuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des maux de tête, des nausées, et des troubles de la conscience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes neurologiques spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme la confusion, la faiblesse musculaire ou des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur est souvent diffuse et peut s'intensifier avec le mouvement ou la lumière."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'origine du cancer et de son stade."
}
},
{
"@type": "Question",
"name": "Peut-on avoir de la fièvre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre est fréquente et peut accompagner d'autres symptômes de méningite."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la méningite carcinomateuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de prévention spécifique, mais un suivi régulier des cancers peut aider."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, éviter le tabac et l'alcool peut réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas la méningite carcinomateuse, mais protègent d'autres types."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le dépistage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce des cancers peut aider à éviter des complications comme la méningite."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent augmenter le risque de développer un cancer."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal inclut la chimiothérapie intrathécale pour cibler les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Des corticostéroïdes sont-ils utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être administrés pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment gérer la douleur ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analgésiques et des traitements symptomatiques sont utilisés pour soulager la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques peuvent proposer des thérapies ciblées ou immunothérapies."
}
},
{
"@type": "Question",
"name": "Quel suivi est nécessaire après traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est essentiel pour surveiller la réponse au traitement et les récidives."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des déficits neurologiques, des infections et des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "La méningite carcinomateuse peut-elle être fatale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être fatale si non traitée, en raison de l'aggravation des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent gravement affecter la qualité de vie, entraînant des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de récidive ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de récidive est élevé, surtout si le cancer primaire n'est pas contrôlé."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Quels cancers sont associés à la méningite carcinomateuse ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et les lymphomes sont souvent associés à cette condition."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes ayant des antécédents de cancer."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que les hommes peuvent être plus à risque que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils un facteur ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de méningite carcinomateuse."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements comme la radiothérapie peuvent augmenter le risque de méningite carcinomateuse."
}
}
]
}
]
}
Spinal neuraxis leptomeningeal metastasis (LM) relapse in glioblastoma is an uncommon event that is challenging to manage. This study aims to determine the incidence, associated factors, and outcome o...
Patients managed for glioblastoma using the EORTC-NCIC (Stupp) Protocol from 2007 to 2019 were entered into a prospective ethics-approved database. Follow-up included routine cranial MRI surveillance ...
Four-hundred-and-seven patients were eligible, with median follow-up of 60 months for surviving patients. Eleven (2.7%) had LM at first relapse and in total 21 (5.1%) experienced LM in the entire foll...
LM relapse is an uncommon but not rare event in patients managed radically for glioblastoma. It is associated with poor outcome with the majority of patients deceased within two months of recognition....
The present review aimed to establish an understanding of the pathophysiology of leptomeningeal disease as it relates to late-stage development among different cancer types. For our purposes, the focu...
Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (N...
EGFR-mutated NSCLC patients who developed BM (the BM cohort) or LM progression (the LM cohort) were included, having received furmonertinib 160 mg daily as second-line or later treatment, with or with...
Totally 12 patients in the BM cohort and 16 patients in the LM cohort were included. Almost one half of patients in the BM cohort and a majority in the LM cohort had a poor physical status, with a Eas...
Single-agent furmonertinib 160 mg or in combination of anti-angiogenic agent is an optional salvage therapy for advanced NSCLC patients who developed BM/LM progression from prior EGFR-TKI treatment, w...
Non-small cell lung cancer with leptomeningeal metastasis (NSCLC-LM) is emerging as a new management challenge for oncologists and is associated with poor prognosis. This study aimed to investigate th...
This retrospective study included 97 patients with NSCLC-LM between January 2015 and October 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated. Gene mutations were detecte...
The median PFS and OS were 8.4 (95 % confidence interval [CI]: 4.839-11.901) and 14.0 (95 % CI: 9.254-18.746) months, respectively. Sixty-seven patients harboured epidermal growth factor receptor-muta...
CSF ctDNA detected using NGS had a high sensitivity for NSCLC-LM, showing high potential in detecting driver and drug-resistant gene mutations. Genomic profiles, combined with clinically relevant prog...
The prognosis of patients with leptomeningeal metastasis (LM) remains poor. Circulating tumour DNA (ctDNA) has been proven to be abundantly present in cerebrospinal fluid (CSF); hence, its clinical im...
We conducted a retrospective study of 35 lung adenocarcinoma (LUAD) patients with LM, and matched CSF and plasma samples were collected from all patients. All paired samples underwent next-generation ...
LM showed genetic heterogeneity, in which CSF had a higher detection rate of ctDNA (P = 0.003), a higher median mutation count (P < 0.0001), a higher frequency of driver mutations (P < 0.01), and more...
CSF ctDNA could provide a more comprehensive genetic landscape of LM, indicating the potential metastasis-related and EGFR-TKI resistance mechanisms of LM patients. In addition, genotyping of CSF comb...
The prognosis and prognostic factors of patients receiving whole-brain radiotherapy (WBRT) for leptomeningeal metastasis (LM) from lung adenocarcinoma have not been established. Particularly, the impa...
Leptomeningeal metastasis (LM) is a complication of surgery for brain metastasis and is a risk factor of poor prognosis. The risk of LM is particularly high after surgery for a breast cancer metastasi...
Ten patients with brain metastases of breast cancer presented LM after surgical resection were analyzed by whole-exome sequencing....
A chromodomain-helicase-DNA-binding protein 5 (CHD5) gene alteration was detected in nine cases (90%), including a nonsynonymous variant in four cases and copy number deletion in five cases. CHD5 prot...
These results suggested that the CHD5 gene alteration was associated with LM after surgical resection of breast cancer brain metastases. Searching for the gene alteration might predict the LM risk aft...
Leptomeningeal spread with carcinomatous meningitis is a severe complication of glioblastoma, with a poor prognosis. Diagnosis is challenging, as the sensitivity of classic diagnostic investigations r...
A 71-year-old woman was admitted to our hospital for recurrent episodes of high fever and xanthochromic meningitis, with subacute onset. Her past medical history was significant for a left temporal gl...
The case describes an unusual clinical presentation of a patient with glioblastoma associated leptomeningeal dissemination, as high fever and xanthochromic CSF could raise important diagnostic and the...
Nasopharyngeal carcinoma (NC) is an epithelial tumor with distinctive prevalence in East and Southeast Asia. Most patients with NC only experience regional metastasis. In cases of distant metastasis, ...
Leptomeningeal metastases represent an aggressive stage of cancer with few durable treatment options. Improved understanding of cancer biology, neoplastic reliance on oncogenic driver mutations, and c...